PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278797ArticlesСтатьиHOW TO ACHIEVE EFFECTIVE GLYCEMIC CONTROL AND REDUCE THE RISK OF VASCULAR COMPLICATIONS DUE TO USING SULFONYLUREA MEDICATIONSКАК ДОСТИЧЬ ЭФФЕКТИВНОГО КОНТРОЛЯ ГЛИКЕМИИ И СНИЗИТЬ РИСК СОСУДИСТЫХ ОСЛОЖНЕНИЙ С ПОМОЩЬЮ ПРЕПАРАТОВ СУЛЬФОНИЛМОЧЕВИНЫBiryukovaElena Valer'evnaБирюковаЕлена Валерьевна

МГМСУ, Москва

pl?midmagidsidYeV httpwwwpharmatecarucgi-binstatyiМГМСУ, Москва15022011183NO3 (2011)№3 (2011)182323022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278797

Type 2 diabetes mellitus (DM2) is disease with dangerous severe complications leading to high morbidity and reduced quality of life. Prevention of vascular complications is an important task in modern medicine. Therefore, results of studies concerned with glycaemic target in DM2 have an important significance. The article discusses pharmacological characteristics, mechanisms of action, efficacy and safety of sulfonylurea medications. It is emphasized that the use of modern sulfonylurea medications contributes to achieving the main goals of treatment of DM - long-term metabolic control and prevention or delay of development of vascular complications.

Сахарный диабет типа 2 (СД2) опасен тяжелыми осложнениями, приводящими к высокой инвалидизации и снижению качества жизни. Предотвращение сосудистых осложнений - важная задача современной медицины. В связи с этим большое значение приобретают результаты исследований, касающихся обеспечения целевых значений гликемии при СД2. Обсуждаются фармакологических характеристики, механизмы действия, вопросы эффективности и безопасности производных сульфонилмочевины. Подчеркивается, что применение современных препаратов сульфонилмочевины способствуют достижению основных целей лечения СД - обеспечению долгосрочного метаболического контроля и предотвращению или отсрочке развития сосудистых осложнений.

type 2 diabetes mellitusglycemic controlcardiovascular complicationshypoglycemic therapysulfonylurea medicationsgliclazideсахарный диабет типа 2гликемический контрольсосудистые осложнениясахароснижающая терапияпроизводные сульфонилмочевиныгликлазидWild S, Roglic A, Green R, et al. Global prevalence of diabetes: estimates for year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.Yi Y, Philips Z, Bergman G, et al. Economic models in type 2 diabetes. Curr Med Res Opin 2010;26(9):2105-18.Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. // Сахарный диабет 2007. № 3. C. 55-7.Adeghate E, Schatiner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006;1084(1):1-29.Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agent? Int J Clin Pract 2009;63:321-32.Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-45.Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002;45(7):1-4.Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the STENO-2 study. Diabetes Care 2008;31:1510-15.Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.Ihnat M.A. The "metabolic memory", the new challenge of diabetes. Diabet Med 2007;24:582-86.Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.Kahn SE. The relative contributions of insulin resistance and ß-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003:46(1):3-19Leahy JL, Hirsch IB, Peterson KA, et al. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95(9):4206-16.Kimmel B, Inzucchi EM. Oral agents for type 2 diabetes: an Update. Clin Diabetes 2005;23(2):64-76.DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.Siconolfi-Baez L, Banerji M, Lebovitz H. Characterization and significance of sulphonylurea receptors. Diabetes Care 1990;13(3):2-8.Aguilar-Bryan L, Nichols CG, Wechsler SF. Cloning of the β cell high affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-26.Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003;81(2):133-76.Schmitz O, Lund S, Andersen PH, et al. Optimizing insulin secretogogue therapy in patients with type 2 diabetes. Diabetes Care 2002;5:342-46.Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.Guillausseau PJ. Hyperglycemie et hypoglycemiants: risques vasculaires. Real Cardiol 2005;207:39-42.Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.Trovati M, Burzacca S, Mularoni E, et al. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Diabetologia 1991;34:662-67.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes. (UKPDS 34). Lancet 1998;352:837-53.Khaled AA, Sekaran M, Ikram SI. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomedical Research 2010;21(2):147-55.Zoungas S, Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann N Y Acad Sci 2010;1212(1):29-40.Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49:17-20.Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004;18:113-19.